CIPLA LTD vs IOL CHEM AND PHARMA LTD

A side-by-side comparison of CIPLA LTD (CIPLA) and IOL CHEM AND PHARMA LTD (IOLCP) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs IOLCP on 13 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability40
  • Growth20
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

CIPLA takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.32
P/E ratio
40.34
3.42
P/B ratio
3.15
0.92%
Dividend yield
0.52%
₹48.02
EPS
₹4.69

Profitability

CIPLA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
7.67%
15.00%
Return on capital
11.00%
21.00%
EBITDA margin
11.11%
13.71%
Net margin
5.94%

Growth

CIPLA takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
1.51%
10.88%
Profit CAGR (3Y)
-0.57%

Size & financial health

CIPLA takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.14L Cr
Market cap
₹5,543 Cr
₹28,163 Cr
Revenue
₹2,319 Cr
₹3,862 Cr
Net profit
₹138 Cr
0.00
Debt / equity
0.08
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
IOL CHEM AND PHARMA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 22.1%", "Promoter holding has increased by 4.80% over last quarter."]
  • ["Stock is trading at 3.18 times its book value", "The company has delivered a poor sales growth of 3.35% over past five years.", "Company has a low return on equity of 7.74% over last 3 years."]
CIPLA LTD full analysis IOL CHEM AND PHARMA LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.